Therapeutic Asset Ratings
462 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
kd033
Neoplasm
Kadmon, a Sanofi Company
P1
C
(36)
ly3200882
Neoplasm
Eli Lilly and Company
P1
C
(36)
LYSINE
Solid Tumor
ITM Solucin GmbH
P1
C
(36)
m1-c6v1
Neoplasm
Guangzhou Virotech Pharmaceutical Co., Ltd.
P1
C
(36)
MAT2A-IN-9
Neoplasm
IDEAYA Biosciences
P1
C
(36)
Max-10181
Neoplasm
Maxinovel Pty., Ltd.
P1
C
(36)
Max-40279-01
Neoplasm
Maxinovel Pty., Ltd.
P1
C
(36)
Mem-288 Intratumoral
Neoplasm
Memgen, Inc.
P1
C
(36)
Micvotabart
Neoplasm
Pyxis Oncology, Inc
P1
C
(36)
mq719
Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(36)
Mrtx0902
Neoplasm
Mirati Therapeutics Inc.
P1
C
(36)
Mrtx1133
Neoplasm
Mirati Therapeutics Inc.
P1
C
(36)
Mrtx1719
Neoplasm
M.D. Anderson Cancer Center
P1
C
(36)
Msk-Tcr5
Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(36)
Neoantigen Mrna Personalised Cancer Sw1115C3
Neoplasm
Stemirna Therapeutics
P1
C
(36)
Neo-T
Neoplasm
BGI, China
P1
C
(36)
Nerofe
Neoplasm
Georgetown University
P1
C
(36)
nib101
Neoplasm
Noile-Immune Biotech, Inc
P1
C
(36)
nkt3447
Neoplasm
NiKang Therapeutics, Inc.
P1
C
(36)
nkt3964
Neoplasm
NiKang Therapeutics, Inc.
P1
C
(36)
np-101
Neoplasm
M.D. Anderson Cancer Center
P1
C
(36)
Oberotatug Ravtansine
Neoplasm
Oxford BioTherapeutics Ltd
P1
C
(36)
Oct-598
Neoplasm
Oscotec Inc.
P1
C
(36)
Ono-4538
Neoplasm
Ono Pharmaceutical Co., Ltd.
P1
C
(36)
Ono-7428
Neoplasm
Ono Pharmaceutical Co., Ltd.
P1
C
(36)
Showing 351 to 375 of 462 assets
Previous
Page 15 of 19
Next
